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bjectives We investigated the impact of sex on outcomes after percutaneous coronary interven-
ion (PCI) with drug-eluting stent (DES).
ackground Women have a higher risk of adverse outcomes after PCI than do men. However, long-
erm outcomes of women after contemporary PCI with DES have not been fully investigated.
ethods We performed a retrospective cohort study of 4,936 consecutive patients (28.2% women)
ho underwent PCIs between 2000 and 2004, before and after introduction of DES (bare-metal
tent [BMS] group: n  2,131, DES group: n  2,805), to assess the impact of sex on long-term PCI
utcomes and to compare outcome after PCI of women between the DES and BMS eras.
esults Compared with men, women undergoing PCIs were 5 years older and more frequently
ave comorbidities such as diabetes mellitus and hypertension. In patients treated throughout the
MS and DES eras, there were no differences by sex for risk of all-cause death, myocardial infarction,
r target vessel revascularization 3 years after procedure. The procedural complexity was higher in
he DES era, nevertheless, risk for target vessel revascularization and major adverse cardiac event at
years were signiﬁcantly lower in women treated with DES than in women treated with BMS (ad-
usted hazard ratio [HR] for target vessel revascularization: 0.52 [95% conﬁdence interval (CI): 0.36 to
.75], adjusted HR for major adverse cardiac event: 0.63 [95% CI: 0.48 to 0.83]).
onclusions Although women had worse baseline characteristics, no differences in 3-year out-
omes were observed between men and women. Compared with BMS use, DES use has decreased
evascularization rate equally in women and men. (J Am Coll Cardiol Intv 2009;2:603–10) © 2009
y the American College of Cardiology Foundation
rom Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.anuscript received February 9, 2009, accepted March 4, 2009.
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604oronary heart disease remains the leading cause of death
mong men and women in developed countries (1), and in
urope, around 25% of coronary revascularization is per-
ormed on women (2). In the early balloon angioplasty era,
everal studies found that female sex was an independent
redictor of in-hospital mortality and that compared with
en, women had lower rates of angiographic success, higher
ncidence of procedural complications and in-hospital
eath, and worse long-term outcomes after percutaneous
See page 611
oronary intervention (PCI) (3–5). In the bare-metal stent
BMS) era, sex-based differences in outcomes have de-
reased in patients undergoing PCI (6,7). In a large pro-
pective registry study of 4,374 patients treated with BMS,
omen had lower rates of restenosis at 6-month angio-
graphic follow-up compared
with men, and women less fre-
quently required target vessel
revascularization (TVR) at 1
year: female sex was an inde-
pendent predictor of freedom
from restenosis (8). Further-
more, a recent study (9) per-
formed in patients treated with
BMS demonstrated that fe-
male sex conferred a long-term
survival advantage after PCI
despite the presence of higher
risk characteristics.
Clinical practice of PCI has
changed since the introduction
of the drug-eluting stent (DES)
with a significantly lower rate of
restenosis compared with BMS
se (10). There is currently a paucity of published data
vailable on the comparison of sex after PCI using DES.
ivotal trials of sirolimus-eluting stents (SES) and
aclitaxel-eluting stents (PES) have included only a small
umber of women and were limited to patients with elective
CI and selective angiographic characteristics. In these
ow-risk populations, sex was not independently associated
ith adverse outcomes (11,12). Recently, using the National
eart, Lung, and Blood Institute (NHLBI) dynamic reg-
stry including high-risk patients, Abbott et al. (13) reported
hat adjusted 1-year outcomes in BMS and DES were
ndependent of sex. However, the impact of sex on long-
erm outcome in unselected patients after PCI has not yet
een fully investigated. Therefore, we performed an analysis
sing the RESEARCH (Rapamycin-Eluting Stent Evalu-
ted at Rotterdam Cardiology Hospital) and T-SEARCH
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
ACE  major adverse
ardiac event
I  myocardial infarction
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
IMI  Thrombolysis In
yocardial Infarction
VR  target vessel
evascularizationTaxus-Stent Evaluated at Rotterdam Cardiology Hospital)egistries’ data to assess the impact of sex on long-term PCI
utcomes and to compare outcome after PCI of women
etween the DES and BMS eras.
ethods
tudy design and patient population. Between January 1,
000, and December 31, 2004, 5,358 patients underwent
CI in our institution using BMS, SES, or PES. Initially,
ll patients were treated with BMS, but on April 16, 2002,
ur institution adopted the use of SES (Cypher, Cordis,
arren, New Jersey) as the default strategy for all coronary
nterventions, as part of the RESEARCH registry (14). On
ebruary 16, 2003, SES was replaced by PES (TAXUS,
oston Scientific, Natick, Massachusetts) as the default
tent, as part of the T-SEARCH registry (15). The exclu-
ion criteria were PCI for a lesion involving a previously
mplanted stent (n  287) or patients receiving only BMS
n  135) in the DES era, because of the unavailability of
he adequate size of DES (Fig. 1). In total, 4,936 patients
ere included in the current study. We defined the BMS
roup as patients treated in a period before introduction of
ES (January 2000 to April 2002, n  2,131) and the DES
roup as those treated after introduction of SES (April 2002
o December 2004, n  2,805).
rocedures and medications. All procedures were per-
ormed according to standard clinical guidelines at the time
14,15). During this period of study, primary PCI was the
efault strategy for all patients with ST-segment elevation
yocardial infarction presenting within 6 h of symptom
nset. The patients are transferred either directly by the
mbulance service or by local emergency departments di-
ectly to our catheter laboratory. Angiographic success was
Figure 1. A Flowchart of Patient Selection
Out of 5,358 patients who underwent percutaneous intervention in a single
center from 2000 to 2004, 4,936 patients were included in this analysis
after exclusion of 422 patients. BMS  bare-metal stent(s); DES  drug-
eluting stent(s).
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605efined as a residual stenosis 30% by visual analysis in the
resence of Thrombolysis In Myocardial Infarction (TIMI)
ow grade 3. All patients were pre-treated with 300 mg of
lopidogrel. At least 1-month of clopidogrel treatment (75
g/day) was recommended for patients treated with BMS.
lopidogrel was prescribed for 3 or 6 months for patients
ith SES depending of the complexity of the procedure and
or 6 months for patients treated with PES. Life-long
spirin therapy was recommended in all patients.
nd point deﬁnitions and clinical follow-up. The primary
nd point was major adverse cardiac event (MACE), de-
ned as all-cause death, nonfatal myocardial infarction (MI)
rrespective of the stented vessel or TVR. Secondary end
oints included all-cause mortality, any MI, TVR, target
esion revascularization, definite stent thrombosis, and the
omposites of all-cause death or nonfatal MI. Myocardial
nfarction was diagnosed by a rise in creatine kinase-MB3
imes the upper limit of normal (16). Target vessel revas-
ularization was defined as a repeat revascularization of a
esion in the same epicardial vessel treated in the index
rocedure (17). Target lesion revascularization was defined
s a repeat intervention in the stent or in the 5-mm
egments proximal or distal to the stent. Hypercholesterol-
mia was defined as a fasting serum cholesterol level 5.5
mol/l or use of lipid-lowering therapy at the time of the
rocedure. Hypertension was defined as blood pressure
140/90 mm Hg or the use of antihypertensive medica-
ions. Stent thrombosis was defined as angiographically
efined thrombosis with TIMI flow grade 0 or 1 or the
resence of a flow-limiting thrombus, accompanied by acute
ymptoms, irrespective of whether there had been an inter-
ening reintervention (18). The timing of stent thrombosis
as categorized as early (within 30 days after implantation),
ate (between 30 days and 1 year after implantation), or very
ate (more than 1 year after implantation) (19).
ollow-up data. Survival data for all patients were obtained
rom municipal civil registries. A questionnaire was subse-
uently sent to all living patients with specific questions on
ehospitalization and MACE year by year. As the principal
egional cardiac referral center, repeat revascularizations,
ither percutaneous or surgical, are normally performed at
ur institution and recorded prospectively in our database.
or patients who suffered an adverse event at another center,
edical records or discharge letters from the other institu-
ions were systematically reviewed. General practitioners
nd referring physicians were contacted for additional in-
ormation if necessary.
tatistical analysis. Continuous variables are presented as
ean  SD, whereas categorical variables are expressed as
ercentages. Statistical comparison was made between
omen and men and stratified by stent type (BMS and
ES). Comparisons among the groups were performed by
isher exact test for categorical variables. All statistical tests
ere 2-tailed, and a p value of 0.05 was considered Mtatistically significant. The incidence of events over time
as studied with the Kaplan-Meier method, and log-rank
ests were applied to evaluate the difference. Patients lost to
ollow-up were considered at risk until the date of last
ontact, at which point they were censored. Cox propor-
ional hazard methods were used to estimate unadjusted and
djusted risk ratios of clinical events at each year in relation
o sex and stent type. Models were adjusted for age,
ardiogenic shock, presentation with acute MI or unstable
ngina, hypertension, current smoking, dyslipidemia, dia-
etes, multivessel disease, family history of coronary artery
isease, previous PCI, previous MI, previous coronary artery
ypass graft, treatment of chronic total occlusion, bifurca-
ion, bypass graft or left main lesion, American Heart
ssociation classification B2 or C, total stented length,
umber of implanted stents, and recommended duration of
lopidogrel. Cox proportional-hazards models adjusted with
he same variables as well as stent type also were used to
ssess relative risks of 3-year MACE in female sex com-
ared with male sex among patient subgroups. Statistical
nalysis was performed with SPSS version 12.0 for windows
SPSS Inc., Chicago, Illinois).
esults
mong 4,936 patients included in the analysis, 3,542
71.8%) were men and 1,394 (28.2%) were women. A total
f 2,131 patients received BMS (596 women and 1,535
en), and 2,805 patients were treated with DES (798
omen and 2,007 men). Baseline and procedural character-
stics stratified by sex and stent type are depicted in Table 1.
mong patients treated with BMS, women were on average
pproximately 5 years older; more often had diabetes,
ypertension, current smoking habit, and left main disease,
nd less often had previous MI. Women more often
nderwent PCI for unstable angina but less often for an
cute MI. Recommended clopidogrel duration was longer
han in men, but glycoprotein IIb/IIIa were less frequently
sed in women.
In demographic and procedural characteristics, differ-
nces among men and women receiving DES were similar
o differences observed in patients with BMS. However, in
he DES era, the rates of left main disease and duration of
lopidogrel administration were comparable between men
nd women. Furthermore, women have lower rates of
ultivessel disease, bypass graft disease, and smaller diam-
ter of stent used.
Clinical follow-up was available in 4,936 patients (98.9%:
ale 98.8%, female 99.3%) with a median duration of
ollow-up of 1,520 days. Cumulative incidences of clinical
nd points up to 3 years are presented in Table 2. In patients
ith BMS and DES, there were no differences by sex for
ates of all-cause death, MI, TVR, stent thrombosis, and
ACE throughout the 3 years after procedure.
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606ES versus BMS in women and men. Among the subgroups of
omen and men, treatment for acute MI was more frequent in
atients with DES than BMS. Risk factors such as hyperten-
ion, family history, and current smoking were more frequently
bserved in patients with DES. The procedural complexity was
igher in DES, illustrated by an increase in the treatment of
ype C lesions and bifurcations. In DES patients, when
Table 1. Patient Baseline Characteristics According to Sex and Stent Type
BMS (n  2,131)
Women
(n  596)
Men
(n  1,535) p Values
Age, yrs 65.5  11.9 59.9  11.3 0.001
Presentation SA 42.3 40.1 0.38
Presentation UA 41.6 33.9 0.001
Presentation acute MI 16.1 26.0 0.001
Cardiogenic shock 1.0 1.1 1.0
Diabetes mellitus 16.9 11.4 0.001
Hypertension 41.3 29.1 0.001
Hypercholesterolemia 42.1 43.2 0.66
Family history 23.2 20.9 0.27
Current smoking 20.6 26.3 0.007
Previous PCI 10.2 9.8 0.75
Previous CABG 10.4 11.1 0.7
Previous MI 28.7 35.8 0.002
Multivessel disease 50.7 54.3 0.13
Treated vessels*
LAD 56.2 54.2 0.41
LCX 29.9 30.6 0.75
RCA 41.6 38.9 0.26
LM 5.2 3.1 0.021
Bypass 3.9 5.3 0.18
Bifurcation 4.7 2.6 0.02
Lesion type†
A 19.6 17.7 0.29
B1 32.9 35.2 0.34
B2 48.2 45.5 0.29
C 32.9 36.3 0.14
Multivessel treatment 32.6 28.7 0.08
No. of lesions intended to treat 1.79  0.91 1.74  0.92 0.3
No. of lesions successfully treated 1.74  9.92 1.70  0.91 0.89
No. of implanted stents 1.89  1.26 1.83  1.19 0.42
Total stented length per patient 28.8  29.6 28.9  20.3 0.91
Average stent diameter 3.21  0.49 3.33  0.51 0.72
Chronic total occlusion 8.7 9.2 0.8
Glycoprotein IIb/IIIa 27.2 34.7 0.001
Clopidogrel prescription duration,
months
2.37  2.69 2.25  2.06 0.04
Angiographic success of all lesions 95.5 95.6 0.91
Values are expressed as % or mean SD.
*Expressed as percentage of patients with each vessel type, hence total100%. †Expressed as per
BMSbare-metal stent(s); CABG coronary arterybypassgraft; DESdrug-eluting stent(s); LA
PCI percutaneous coronary intervention; RCA right coronary artery; SA stable angina; UAompared with BMS patients, total stented length and number wf stents increased, but the average stent diameter decreased.
ates for TVR and MACE at any time point were signifi-
antly lower in women and men treated with DES than in
atients of both sexes treated with BMS (Table 2, Fig. 2). At
he 3-year follow-up, definite stent thrombosis was higher in
en with DES than in men treated with BMS (2.6% vs. 1.5%,
og-rank: p  0.04), whereas it was similar in women treated
DES (n  2,805)
Women
(BMS vs. DES)
p Values
Men
(BMS vs. DES)
p Values
Women
 798)
Men
(n  2,007) p Values
.4  11.5 60.7  11.0 0.001 0.82 0.03
42.5 39.6 0.16 0.96 0.76
35.5 28.7 0.001 0.02 0.001
22.1 31.4 0.001 0.006 0.001
2.3 2.2 1.0 0.1 0.01
20.8 14.8 0.001 0.07 0.003
53.4 36.5 0.001 0.001 0.001
51.4 54.1 0.21 0.001 0.001
34.7 31.6 0.12 0.001 0.001
23.7 27.7 0.03 0.19 0.1
8.3 7.0 0.26 0.22 0.053
6.8 7.5 0.57 0.02 0.001
23.7 29.9 0.001 0.001 0.001
48.4 55.4 0.001 0.42 0.95
57.6 56.9 0.74 0.62 0.72
27.1 33.4 0.001 0.25 0.34
42.4 37.4 0.016 0.78 0.28
4.0 4.7 0.48 0.3 0.001
1.5 3.9 0.001 0.008 0.02
11.9 12.4 0.75 0.001 0.001
13.4 12.8 0.66 0.002 0.001
31.2 29.0 0.27 0.52 0.001
45.0 48.9 0.07 0.25 0.5
42.5 45.6 0.14 0.001 0.001
28.6 30.5 0.32 0.11 0.89
6  0.96 1.79  0.97 0.59 0.66 0.47
2  0.96 1.72  0.98 0.97 0.68 0.31
2  1.43 2.23  1.43 0.83 0.001 0.001
.5  29.3 43.0  30.7 0.22 0.001 0.001
5  0.53 2.95  0.55 0.001 0.001 0.001
8.4 8.6 0.88 0.85 0.15
17.2 25.1 0.001 0.001 0.001
0  2.70 5.60  3.10 0.37 0.001 0.001
96.1 94.2 0.04 0.59 0.14
of patients with each lesion type, hence total100%.
t anterior descendingartery; LCX left circumflexartery; LM leftmain;MImyocardial infarction;
e angina.(n
65
1.7
1.7
2.2
41
2.8
5.5
centage
D lefith DES or BMS (2.0% vs. 1.8%, p  0.52).
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607ultivariate analyses. Unadjusted and adjusted models
tratified by stent type showed that female sex did not confer
benefit or risk for any adverse events (Table 3), whereas
he use of DES was associated with a lower risk of TVR or
ACE in men and women at 1-, 2-, and 3-year follow-ups.
Table 2. Clinical Outcomes Stratified by Sex and Stent Type
BMS Era (n  2,131)
Women
(n  596)
Men
(n  1,535) p Values
At 1 year (cumulative)
Death 8.0 6.0 0.1
Myocardial infarction 3.1 3.3 0.86
Target vessel revascularization 11.1 10.0 0.48
Major adverse cardiac events 19.1 16.5 0.16
Deﬁnite stent thrombosis 1.8 1.3 0.43
At 2 years (cumulative)
Death 9.2 8.4 0.55
Myocardial infarction 3.9 4.0 0.94
Target vessel revascularization 12.8 12.8 0.96
Major adverse cardiac events 22.3 21.3 0.55
Deﬁnite stent thrombosis 1.8 1.5 0.58
At 3 years (cumulative)
Death 11.6 11.0 0.65
Myocardial infarction 4.3 4.3 0.95
Target vessel revascularization 14.7 13.9 0.63
Major adverse cardiac events 25.9 24.5 0.45
Deﬁnite stent thrombosis 1.8 1.5 0.66
Bold values are statistically significant.
Abbreviations as in Table 1.
Figure 2. Kaplan-Meier Curve of MACE up to 3 Years After Index
Procedure Among 4 Groups
Major adverse cardiac event (MACE) rates were signiﬁcantly lower in
women (solid red line) and men (dotted red line) treated with DES than
in patients of both sexes treated with BMS (solid black line for women,v
dotted black line for men). Abbreviations as in Figure 1.t 3 years, the risk of definite stent thrombosis was higher
n men with DES versus BMS in univariate analysis (hazard
atio [HR]: 1.7 [95% confidence interval (CI): 1.03 to
.81]); this difference was not significant in the adjusted
odel (adjusted HR: 1.83 [95% CI: 0.93 to 3.59]).
Figure 3 represents the results of subgroup multivariate
nalysis of the association between sex and the risk of
ACE at 3-year follow-up in patients treated with DES.
emale sex did not confer a benefit or risk for MACE in any
roups except for the subpopulation presenting with acute
I (adjusted HR women vs. men: 1.37 [95% CI: 1.02 to
.85]).
iscussion
he main findings of the current analysis from the
-SEARCH and RESEARCH registries with respect to
ex are as follows: 1) DES use was associated with lower
ates of TVR or MACE in both sexes; 2) after stratification
or stent type, all clinical end points at any time points up to
years were similar between both sexes; and 3) in the
ubpopulation of patients presenting with acute MI, the risk
f MACE at 3 years was higher in women than in men.
Only few data are available regarding sex differences in
he DES era. In the TAXUS-IV–2 Year Data (TAXUS-
V) trial, they found that women had more comorbidities
nd an overall higher rate of repeat PCI than men did (7.6%
DES Era (n  2,805)
Women
(DES vs. BMS)
p Values
Men
(DES vs. BMS)
p Values
omen
 798)
Men
(n  2,007) p Values
6.8 5.3 0.13 0.39 0.35
2.7 3.2 0.54 0.64 0.77
6.7 6.2 0.65 0.005 0.0001
14.4 12.2 0.12 0.02 0.0004
1.1 1.7 0.31 0.37 0.34
8.5 7.5 0.38 0.62 0.32
3.3 3.7 0.56 0.54 0.74
8.2 8.4 0.88 0.006 <0.0001
17.4 16.4 0.46 0.02 0.0002
1.4 2.3 0.16 0.63 0.07
10.2 9.5 0.52 0.44 0.18
4.6 4.4 0.96 0.91 0.98
10.3 9.7 0.72 0.02 0.0001
20.9 19.1 0.27 0.03 0.0001
2.0 2.6 0.62 0.52 0.04W
(ns. 3.2%, p  0.03), but the restenosis rates and late loss
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608ere similar by sex in the DES arm of the study (11). In a
ooled analysis of 1,748 patients from 4 randomized SES
ersus BMS trials, Solinas et al. (12) reported that despite
ess favorable baseline characteristics in women compared
ith men, at 1 year, the clinical benefits of SES were
ndependent of sex, with reductions of binary restenosis
oth in women (6.3% vs. 43.8%) and in men (6.4% vs.
5.6%). Recently, using data from NHLBI dynamic
egistry, including high-risk patients, Abbott et al. (13)
eported that patients with DES had a lower rate of
epeat PCI in both sexes (14.1% in women vs. 9.5%, p 
.02; 12.0% in men vs. 8.8%, p  0.02) at 1 year. Our
ndings not only confirm the results of previous studies
Table 3. Unadjusted and Adjusted HR for Sex (Women vs. Men) in Each St
HR Women vs. Men
BMS DES
At 1 year
Death 1.34 (0.94–1.90) 1.29 (0.93–1.79)
Adjusted 1.15 (0.75–1.75) 1.16 (0.78–1.72)
Myocardial infarction 0.95 (0.55–1.63) 0.86 (0.53–1.42)
Adjusted 0.78 (0.41–1.47) 1.08 (0.64–1.83)
Target vessel revascularization 1.11 (0.83–1.50) 1.08 (0.78–1.50)
Adjusted 1.13 (0.83–1.56) 1.16 (0.81–1.64)
Major adverse cardiac events 1.18 (0.94–1.47) 1.19 (0.95–1.49)
Adjusted 1.09 (0.85–1.40) 1.23 (0.96–1.58)
Deﬁnite stent thrombosis 1.36 (0.63–2.93) 0.69 (0.33–1.43)
Adjusted 1.25 (0.54–2.87) 0.71 (0.33–1.55)
At 2 years
Death 1.10 (0.80–1.52) 1.14 (0.85–1.52)
Adjusted 0.90 (0.62–1.31) 1.02 (0.73–1.43)
Myocardial infarction 0.98 (0.60-1.61) 0.87 (0.55–1.38)
Adjusted 0.88 (0.50–1.54) 1.02 (0.63–1.66)
Target vessel revascularization 1.01 (0.77–1.32) 0.98 (0.73–1.31)
Adjusted 1.02 (0.76–1.37) 1.07 (0.78–1.46)
Major adverse cardiac events 1.06 (0.87–1.30) 1.08 (0.88–1.32)
Adjusted 0.98 (0.78–1.23) 1.10 (0.88–1.38)
Deﬁnite stent thrombosis 1.24 (0.58–2.62) 0.63 (0.32–1.22)
Adjusted 1.18 (0.53–2.66) 0.72 (0.36–1.43)
At 3 years
Death 1.07 (0.80–1.42) 1.09 (0.84–1.42)
Adjusted 0.84 (0.61–1.17) 0.92 (0.68–1.25)
Myocardial infarction 0.99 (0.62–1.58) 1.01 (0.68–1.51)
Adjusted 0.90 (0.53–1.53) 1.22 (0.79–1.87)
Target vessel revascularization 1.07 (0.82–1.38) 1.05 (0.80–1.38)
Adjusted 1.08 (0.82–1.43) 1.16 (0.87–1.54)
Major adverse cardiac events 1.08 (0.89–1.30) 1.11 (0.92–1.33)
Adjusted 0.97 (0.79–1.20) 1.11 (0.90–1.37)
Deﬁnite stent thrombosis 1.18 (0.56–2.49) 0.87 (0.50–1.51)
Adjusted 1.15 (0.51–2.55) 1.01 (0.57–1.79)
Values are hazard ratio (95% confidence interval) or p value. Bold values are statistically significant
HR hazard ratio; other abbreviations as in Table 1.ut also suggest that this superiority of DES to lower sevascularization is maintained in both sexes up to 3 years
fter procedure.
In our analysis, women treated with DES had worse
aseline demographics, including older age and higher
revalence of comorbidities, especially diabetes, which is
ssociated with higher rates of restenosis. However, clinical
utcomes were independent of sex with the benefit of DES
ver BMS being almost identical throughout the 3-year
linical follow-up. This is in contrast to previous PCI series
hat have reported an association between sex and clinical
nd angiographic restenosis rates (8,20), but it concurs with
he data from a recent series on 3,223 patients, in which
-year clinically driven revascularization was similar for both
ype or for Stent Type (DES vs. BMS) in Each Sex
HR DES vs. BMS
p Value for Interaction
Between Sex and Stent TypeWomen Men
0.84 (0.57–1.25) 0.88 (0.66–1.16)
0.68 (0.40–1.15) 0.79 (0.53–1.17) 0.73
0.86 (0.46–1.61) 0.95 (0.65–1.38)
0.70 (0.32–1.53) 0.77 (0.46–1.29) 0.73
0.59 (0.41–0.86) 0.61 (0.48–0.78)
0.44 (0.28–0.69) 0.60 (0.44–0.80) 0.89
0.74 (0.57–0.95) 0.73 (0.61–0.87)
0.58 (0.42–0.80) 0.66 (0.52–0.84) 0.35
0.66 (0.27–1.63) 1.32 (0.75–2.32)
0.50 (0.16–1.58) 1.42 (0.67–3.00) 0.1
0.91 (0.64–1.31) 0.89 (0.70–1.12)
0.75 (0.45–1.24) 0.88 (0.64–1.21) 0.81
0.84 (0.47–1.48) 0.94 (0.67–1.33)
0.72 (0.35–1.48) 0.85 (0.52–1.38) 0.75
0.63 (0.44–0.88) 0.64 (0.52–0.80)
0.46 (0.31–0.69) 0.61 (0.47–0.79) 0.88
0.76 (0.60–0.96) 0.75 (0.64–0.87)
0.58 (0.43–0.78) 0.70 (0.57–0.86) 0.42
0.81 (0.34–1.91) 1.59 (0.94–2.68)
0.58 (0.20–1.68) 1.70 (0.84–3.44) 0.23
0.88 (0.64–1.22) 0.87 (0.70–1.07)
0.77 (0.49–1.20) 0.87 (0.66–1.15) 0.92
1.03 (0.61–1.75) 1.00 (0.72–1.38)
0.89 (0.47–1.70) 0.90 (0.57–1.41) 0.76
0.67 (0.49–0.92) 0.68 (0.55–0.83)
0.52 (0.36–0.75) 0.65 (0.51–0.83) 0.87
0.78 (0.62–0.97) 0.75 (0.65–0.87)
0.63 (0.48–0.83) 0.71 (0.59–0.86) 0.41
1.30 (0.59–2.83) 1.7 (1.03–2.81)
0.94 (0.37–2.39) 1.83 (0.93–3.59) 0.51ent T
.exes (13).
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609Our subgroup analysis suggests that women presenting
ith acute MI still have worse outcomes than men do.
ecause there were substantially fewer females than males
19.5% vs. 29.1%) in this subset, it is plausible that this
nequality in proportions could be responsible for the
ailure to reach statistical significance for the outcomes
etween sexes and that even matching would have wors-
ned the outcomes of the female cohort. In general,
nadjusted comparisons of mortality after acute MI have
enerally indicated that women have a poorer outcome
han men (21,22) and have less favorable short-term
utcomes after revascularization procedures (23). In our
nstitution, primary PCI was the default strategy for all
atients with acute MI presenting within 6 h of symptom
nset. Therefore, our results suggest that despite the use
f DES with contemporary PCI techniques, the outcome
f women with ST-segment elevation myocardial infarc-
ion still needs to be improved. In addition to anatomical
ifferences, the basic biological differences in response to
cute MI between men and women have also been
uggested (24). Further investigation in this high-risk
Figure 3. Adjusted Hazard Ratio of Women Versus Men on MACE at Year 3
Female sex was not associated with differential MACE risk from male sex in an
HR women vs. men: 1.37 [95% CI: 1.02 to 1.85]). CI  conﬁdence interval; HR opulation is warranted. otudy limitations. The current study suffers from the
nherent limitations of a nonrandomized trial. There
ere significant differences between BMS and DES and
etween both sexes in terms of baseline demographics.
o compensate for these differences, we have performed
djustments employing multivariate analyses, although
e cannot adjust confounding factors such as changes in
ractice during this period using various material, differ-
nt guidelines, or operator’s experiences. Nevertheless,
hese unselected patients represent real-world practice,
hereas patients enrolled in clinical trials are carefully
elected. In addition, we only investigated angiographi-
ally documented stent thrombosis, using a definition
onsistent with previous reports on stent thrombosis
ither after DES or BMS implantation. The latter may
ave led to an underestimation of the actual incidence of
tent thrombosis, particularly, in patients suffering from
udden cardiac death or silent stent occlusion.
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